These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Discovery, Optimization, and Biological Characterization of 2,3,6-Trisubstituted Pyridine-Containing M Schubert JW; Harrison ST; Mulhearn J; Gomez R; Tynebor R; Jones K; Bunda J; Hanney B; Wai JM; Cox C; McCauley JA; Sanders JM; Magliaro B; O'Brien J; Pajkovic N; Huszar Agrapides SL; Taylor A; Gotter A; Smith SM; Uslaner J; Browne S; Risso S; Egbertson M ChemMedChem; 2019 May; 14(9):943-951. PubMed ID: 30920765 [TBL] [Abstract][Full Text] [Related]
15. Development of a radioligand, [(3)H]LY2119620, to probe the human M(2) and M(4) muscarinic receptor allosteric binding sites. Schober DA; Croy CH; Xiao H; Christopoulos A; Felder CC Mol Pharmacol; 2014 Jul; 86(1):116-23. PubMed ID: 24807966 [TBL] [Abstract][Full Text] [Related]
16. Challenges in the development of an M Wood MR; Noetzel MJ; Poslusney MS; Melancon BJ; Tarr JC; Lamsal A; Chang S; Luscombe VB; Weiner RL; Cho HP; Bubser M; Jones CK; Niswender CM; Wood MW; Engers DW; Brandon NJ; Duggan ME; Conn PJ; Bridges TM; Lindsley CW Bioorg Med Chem Lett; 2017 Jan; 27(2):171-175. PubMed ID: 27939174 [TBL] [Abstract][Full Text] [Related]
17. Synthesis and characterization of chiral 6-azaspiro[2.5]octanes as potent and selective antagonists of the M Bender AM; Carter TR; Spock M; Rodriguez AL; Dickerson JW; Rook JM; Chang S; Qi A; Presley CC; Engers DW; Harp JM; Bridges TM; Niswender CM; Conn PJ; Lindsley CW Bioorg Med Chem Lett; 2022 Jan; 56():128479. PubMed ID: 34838649 [TBL] [Abstract][Full Text] [Related]
18. Characterization of the novel positive allosteric modulator, LY2119620, at the muscarinic M(2) and M(4) receptors. Croy CH; Schober DA; Xiao H; Quets A; Christopoulos A; Felder CC Mol Pharmacol; 2014 Jul; 86(1):106-15. PubMed ID: 24807965 [TBL] [Abstract][Full Text] [Related]
19. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Nawaratne V; Leach K; Suratman N; Loiacono RE; Felder CC; Armbruster BN; Roth BL; Sexton PM; Christopoulos A Mol Pharmacol; 2008 Oct; 74(4):1119-31. PubMed ID: 18628403 [TBL] [Abstract][Full Text] [Related]
20. Further optimization of the M1 PAM VU0453595: Discovery of novel heterobicyclic core motifs with improved CNS penetration. Panarese JD; Cho HP; Adams JJ; Nance KD; Garcia-Barrantes PM; Chang S; Morrison RD; Blobaum AL; Niswender CM; Stauffer SR; Conn PJ; Lindsley CW Bioorg Med Chem Lett; 2016 Aug; 26(15):3822-5. PubMed ID: 27173801 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]